A study to evaluate whether skeletal muscle and lean body mass loss are associated with poorer prognosis in patients with non small cell lung cancer treated with afatinib

Trial Profile

A study to evaluate whether skeletal muscle and lean body mass loss are associated with poorer prognosis in patients with non small cell lung cancer treated with afatinib

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Oct 2015

At a glance

  • Drugs Afatinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Oct 2015 New trial record
    • 06 Sep 2015 Results published in 16th World Conference on Lung Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top